Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Sponsor: Nuwacell Biotechnologies Co., Ltd.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Official title: A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2025-06-06
Completion Date
2028-12-01
Last Updated
2025-08-01
Healthy Volunteers
No
Conditions
Interventions
Allogeneic dopaminergic neural precursor cell(NCR201)
Bilateral implantation
Locations (1)
The First Affiliated Hospital of USTC
Hefei, Anhui, China